This study examines the neural activities of participants undergoing vibro-motor reprocessing therapy (VRT) while experiencing motion sickness. We evaluated the efficacy of vibro-motor reprocessing therapy, a novel therapeutic technique based on eye movement desensitization and reprocessing (EMDR), in reducing motion sickness. Based on visually induced motion sickness in two sets of performed sessions, eight participants were exposed to VRT stimulation in a VRT/non-VRT setting. Simultaneously, brain activity changes were recorded using electroencephalography (EEG) at baseline and during stimulus exposure, and comparisons made across the VRT/non-VRT conditions. A significant reduction in the alpha (8-12 Hz) spectral power was observed in the frontal and occipital locations, consistent across all participants. Furthermore, significant reductions were also found in the frontal and occipital delta (0.5-4 Hz) and theta (4-8 Hz) spectral power frequency bands between non-VRT and VRT conditions (p < 0.05). Our results offer novel insights for a potential nonpharmacological treatment and attenuation of motion sickness. Furthermore, symptoms can be observed, and alleviated, in real-time using the reported techniques. Clinical relevance - Instead of using drugs to treat motion sickness, patients could safely use this VRT technique.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1109/EMBC48229.2022.9871336 | DOI Listing |
Sports Health
December 2024
University of Pittsburgh Medical Center Sports Medicine Concussion Program, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
Background: Factors associated with performance outside of a normative range on dynamic exertion test (EXiT) after sport-related concussion (SRC) remain unknown. This study examined the role of demographic and medical history factors on performance using minimal detectable change (MDC) cutoff scores in athletes being cleared to return to sport (RTS) from SRC.
Hypothesis: Older age, being female, and body mass index (BMI) ≥50th percentile would be associated with worse EXiT performance and with increased likelihood of falling outside the normative MDC score range.
J Oral Maxillofac Surg
November 2024
Associate Professor and Chair, Department of Anesthesiology, Saitama Medical University Hospital, Moroyamacho Irumagun, Japan.
Background: Whether postoperative nausea and vomiting (PONV) contributes to increased postoperative pain (POP) remains unclear, although POP is reported to cause PONV.
Purpose: This study aimed to determine whether PONV following minor oral surgery (MOS) under general anesthesia increases POP.
Study Design, Setting, Sample: The researchers implemented a retrospective cohort study.
Diving Hyperb Med
December 2024
Motion Sickness and Human Performance Laboratory, The Israel Naval Medical Institute, IDF Medical Corps, Haifa, Israel.
Introduction: Diving utilising closed circuit pure oxygen rebreather systems has become popular in professional settings. One of the hazards the oxygen diver faces is central nervous system oxygen toxicity (CNS-OT), causing potentially fatal convulsions. At the same time, divers frequently travel by boat, often suffering seasickness.
View Article and Find Full Text PDFObjective: To explore and validate effective eye movement features related to motion sickness (MS) through closed-track experiments and to provide valuable insights for practical applications.
Background: With the development of autonomous vehicles (AVs), MS has attracted more and more attention. Eye movements have great potential to evaluate the severity of MS as an objective quantitative indicator of vestibular function.
Otol Neurotol
January 2025
Cedars-Sinai Medical Center, Division of Otolaryngology-Head and Neck Surgery, Los Angeles, CA.
Introduction: GLP-1 receptor agonists (GLP-1 RAs) have gained traction in the management of obesity. There is limited literature on the implications of GLP-1 RAs in the field of otolaryngology.
Methods: We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!